MDS Announces Voting Support Agreements
02 Septembre 2009 - 3:09PM
PR Newswire (US)
TORONTO, Sept. 2 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS;
NYSE: MDZ), a leading provider of products and services to the
global life sciences markets earlier today disclosed that it had
entered into an agreement to sell its MDS Analytical Technologies
business to Danaher Corporation (NYSE:DHR) for $650 million in
cash. Further to this announcement, ValueAct Capital and Enterprise
Capital Management Inc., two of the Company's largest shareholders,
who collectively own approximately 23% of the Company's outstanding
common shares, have each entered into an agreement with Danaher
pursuant to which they have agreed to vote their common shares in
favor of the transaction. These agreements are subject to the
ability of the shareholders to change their vote if the Board
changes its recommendation with respect to the transaction. The
completion of the sale of the MDS Analytical Technologies business
is subject to, among various other conditions, shareholder
approval. A Special Meeting of Shareholders is expected to be held
in October 2009. The sale must be approved by two-thirds of the
votes cast at the meeting. MDS anticipates that a management proxy
circular for the shareholder meeting will be mailed to shareholders
later this month and will be available at http://www.sedar.com/,
http://www.sec.gov/edgar.shtml and http://www.mdsinc.com/. About
MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences
company that provides market-leading products and services that
customers need for the development of drugs and diagnosis and
treatment of disease. MDS Inc. is a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 4,200 highly skilled people in 13 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. Caution Concerning Forward-Looking Statements This
document contains forward-looking statements, including statements
with respect to the proposed sale of the MDS Analytical
Technologies business, the proposed use of proceeds from the sale,
the strategy of the remaining business and the Company's intention
to sell other assets of the Company. Some forward-looking
statements may be identified by words like "expects",
"anticipates", "plans", "intends", "indicates" or similar
expressions. The statements are not a guarantee of future
performance, and are inherently subject to risks and uncertainties.
MDS's actual results could differ materially from those expressed
in the forward-looking statements due to these risks and a number
of other factors, including, but not limited to, successful
implementation of structural changes, including restructuring
plans, acquisitions and divestitures including the proposed sale of
the MDS Analytical Technologies business, technical or
manufacturing or distribution issues, the competitive environment
for MDS's products and services, the degree of market penetration
of its products and services, the ability to secure a reliable
supply of raw materials, the impact of our clients' exercising
rights to delay or cancel certain contracts, the strength of the
global economy, the stability of global equity markets, the
availability and cost of financing, the impact of the movement of
the U.S. dollar relative to other currencies, particularly the
Canadian dollar and the euro, uncertainties associated with
critical accounting assumptions and estimates, and other factors
set forth in reports and other documents filed by MDS with Canadian
and U.S. securities regulatory authorities from time to time,
including MDS's quarterly and annual MD A, Annual Information Form,
and Annual Report on Form 40-F for the fiscal year ended October
31, 2008, filed with the U.S. Securities Exchange Commission.
DATASOURCE: MDS Inc. CONTACT: MEDIA: Janet Ko, (905) 267-4226, ;
INVESTORS: Kim Lee, (905) 267-4230,
Copyright